AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25596004 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 41
Study 25596004 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent school-based intervention
Number of subjects: 41
Study 23868532 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 h group (cumulus cell removal 4 h post-insemination)
Number of subjects: 61
Study 23868532 — intervention group
Group type: COMPARATOR
Intervention: 20 h group (cumulus cell removal 20 h post-insemination)
Number of subjects: 61
Study 20623930 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 26
Study 20623930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 20623930 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drink)
Number of subjects: 26
Study 19102589 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 20
Study 19102589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16822114 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral couples therapy plus individual‐based treatment (BCT)
Number of subjects: 138
Study 16822114 — intervention group
Group type: COMPARATOR
Intervention: Individual‐based treatment only (IBT)
Number of subjects: 138
Study 16822114 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational attention control treatment (PACT)
Number of subjects: 138
Study 12626901 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber band ligation
Number of subjects: 55
Study 12626901 — intervention group
Group type: COMPARATOR
Intervention: Stapled hemorrhoidectomy
Number of subjects: 55
Study 10679130 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive infection control program including educational program and single-branded germicidal products for 12 months.
Number of subjects: 890
Study 10679130 — intervention group
Group type: COMPARATOR
Intervention: Existing infection control policies and procedures (Control group).
Number of subjects: 890
Study 9081269 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.6% carbohydrate-electrolyte (CE) solution
Number of subjects: 19
Study 9081269 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificially flavored and colored water)
Number of subjects: 19
Study 8373876 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid (20% of long chain triglycerides)
Number of subjects: 0
Study 8373876 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipofundina (10% each of long and medium-chain triglycerides)
Number of subjects: 0
Study 2431461 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electroresection of the prostate (TURP)
Number of subjects: 24
Study 2431461 — intervention group
Group type: COMPARATOR
Intervention: Bladder neck incision (BNI)
Number of subjects: 24
Study 2431461 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TURP and BNI
Number of subjects: 24
Study 29972213 — intervention group
Group type: EXPERIMENTAL
Intervention: Auraptene enriched test juice (6.0 mg/day)
Number of subjects: 84
Study 29972213 — intervention group
Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 84
Study 26630412 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 39
Study 26630412 — intervention group
Group type: COMPARATOR
Intervention: Non-Motivational Interviewing (non-MI)
Number of subjects: 39
Study 26630412 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic group CBT (for both MI and non-MI)
Number of subjects: 39
Study 24473387 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard continuous blood purification with heparin anticoagulation
Number of subjects: 16
Study 24473387 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous blood purification without anticoagulation
Number of subjects: 16
Study 24473387 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 16
Study 24473387 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin group
Number of subjects: 16
Study 22392567 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 0
Study 22392567 — intervention group
Group type: EXPERIMENTAL
Intervention: Low plasma concentration of DEX (0.04 ng/mL)
Number of subjects: 0
Study 22392567 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma concentration of DEX (0.08 ng/mL)
Number of subjects: 0
Study 20160215 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with poor insight
Number of subjects: 321
Study 20160215 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing neuropsychiatric symptoms
Number of subjects: 321
Study 17698336 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (n=17)
Number of subjects: 37
Study 17698336 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia (n=20)
Number of subjects: 37
Study 15917042 — intervention group
Group type: EXPERIMENTAL
Intervention: Free fruit
Number of subjects: 795
Study 15917042 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid fruit
Number of subjects: 795
Study 15917042 — intervention group
Group type: COMPARATOR
Intervention: No fruit
Number of subjects: 795
Study 12841994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 701
Study 12841994 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 701
Study 10587413 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium therapy for 4 weeks
Number of subjects: 12
Study 10587413 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium therapy (post-treatment)
Number of subjects: 12
Study 10587413 — intervention group
Group type: COMPARATOR
Intervention: Baseline ENO levels in asthmatic children
Number of subjects: 12
Study 10587413 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium therapy
Number of subjects: 12
Study 8692528 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 preoperative therapy (18.10(6) IU/day subcutaneously for 3 consecutive days)
Number of subjects: 50
Study 8692528 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 preoperative therapy
Number of subjects: 50
Study 8692528 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IL-2 preoperative therapy)
Number of subjects: 50
Study 1748776 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural buprenorphine 0.3 mg
Number of subjects: 0
Study 1748776 — intervention group
Group type: COMPARATOR
Intervention: Extradural pentazocine 30 mg
Number of subjects: 0
Study 6632727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethylbiguanide (DMB) in doses of between 1 and 3 g
Number of subjects: 0
Study 6632727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethylbiguanide (DMB)
Number of subjects: 0
Study 31699072 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized 3% hypertonic saline for 3 days (HS3d group)
Number of subjects: 116
Study 31699072 — intervention group
Group type: COMPARATOR
Intervention: Nebulized 3% hypertonic saline for 1 day followed by 0.9% normal saline for 2 days (HS1d group)
Number of subjects: 116
Study 31699072 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HS1d and HS3d)
Number of subjects: 116
Study 28622048 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ‐SC 162 mg qw monotherapy
Number of subjects: 0
Study 28622048 — intervention group
Group type: COMPARATOR
Intervention: TCZ‐SC 162 mg q2w monotherapy
Number of subjects: 0
Study 26164058 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon (PT)
Number of subjects: 330
Study 26164058 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple-stranded hamstring tendon (HT)
Number of subjects: 330
Study 26164058 — intervention group
Group type: EXPERIMENTAL
Intervention: Double bundle using hamstring tendon (DB)
Number of subjects: 330
Study 25315686 — intervention group
Group type: COMPARATOR
Intervention: Powerade (Coca Cola Ltd); 129 kJ.100 mL(‐1)
Number of subjects: 15
Study 25315686 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustagen Sport (Nestle); 417 kJ.100 mL(‐1)
Number of subjects: 15
Study 25315686 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy milk (273 kJ.100 mL(‐1))
Number of subjects: 15
Study 25315686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk (286 kJ.100 mL(‐1))
Number of subjects: 15
Study 25315686 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustagen Sport
Number of subjects: 15
Study 25315686 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy milk
Number of subjects: 15
Study 25315686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk
Number of subjects: 15
Study 25315686 — intervention group
Group type: EXPERIMENTAL
Intervention: Powerade
Number of subjects: 15
Study 25315686 — intervention group
Group type: EXPERIMENTAL
Intervention: All milk trials
Number of subjects: 15
Study 25315686 — intervention group
Group type: EXPERIMENTAL
Intervention: All beverages
Number of subjects: 15
Study 22846245 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress as a mediator
Number of subjects: 663
Study 22846245 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic stressors
Number of subjects: 663
Study 22846245 — intervention group
Group type: EXPERIMENTAL
Intervention: Past-month drinking and problematic drinking
Number of subjects: 663
Study 19076245 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily hygiene with a soft toothbrush and toothpaste (G1)
Number of subjects: 20
Study 19076245 — intervention group
Group type: COMPARATOR
Intervention: Daily hygiene with a soft toothbrush and toothpaste plus immersion in sodium hypochlorite 0.5% for 20 min once a week (G2)
Number of subjects: 20
Study 17499654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.2 mg x kg(‐1) intravenous over 10 minutes)
Number of subjects: 73
Study 17499654 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic sodium chloride solution)
Number of subjects: 73
Study 15211021 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ergometry exercise protocol
Number of subjects: 100
Study 11980113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventolin nebulizer (2.5 mg)
Number of subjects: 78
Study 11980113 — intervention group
Group type: EXPERIMENTAL
Intervention: Berodual (0.25 mg ipratropium bromide and 0.5 mg phenoterol)
Number of subjects: 78
Study 11980113 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrovent (0.5 mg)
Number of subjects: 78
Study 11980113 — intervention group
Group type: EXPERIMENTAL
Intervention: Berotek (1.0 mg by nebulizer Pulmo-Aide 56501)
Number of subjects: 78
Study 11980113 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of beta 2‐adrenomimetic with atrovent
Number of subjects: 78
Study 9531685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sennosides (1 ml/kg, max 75 ml of syrup containing 2.0 mg/ml sennoside A and B)
Number of subjects: 171
Study 9531685 — intervention group
Group type: COMPARATOR
Intervention: Lavage solution only
Number of subjects: 171
Study 9531685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sennosides
Number of subjects: 171
Study 9098257 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminocaproic acid (100 mg/kg every 4 hours; maximum 30 g daily)
Number of subjects: 94
Study 9098257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 9098257 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminocaproic acid
Number of subjects: 94
Study 2523658 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg
Number of subjects: 11
Study 2523658 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 5.0 mg
Number of subjects: 11
Study 2523658 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 7.5 mg
Number of subjects: 11
Study 2523658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 329946 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy for six 12-week courses
Number of subjects: 0
Study 329946 — intervention group
Group type: COMPARATOR
Intervention: Continuation of maintenance chemotherapy for a further six 12-week courses
Number of subjects: 0
Study 329946 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic irradiation to cranium and spine combined with intrathecal methotrexate
Number of subjects: 0
Study 329946 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic treatment
Number of subjects: 0
Study 30054228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed field gel electrophoresis (PFGE) analysis with XbaI
Number of subjects: 88
Study 30054228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed field gel electrophoresis (PFGE) analysis with BlnI
Number of subjects: 88
Study 30054228 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole genome sequencing (WGS) analysis
Number of subjects: 88
Study 30054228 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism (SNP) analysis
Number of subjects: 88
Study 28818607 — intervention group
Group type: COMPARATOR
Intervention: TTFC ≤5 minutes
Number of subjects: 18729
Study 28818607 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFC ≥60 minutes
Number of subjects: 18729
Study 28818607 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding TTFC to lung cancer incidence model
Number of subjects: 18729
Study 26188663 — intervention group
Group type: EXPERIMENTAL
Intervention: High methadone dose (100 mg/day)
Number of subjects: 7
Study 26188663 — intervention group
Group type: EXPERIMENTAL
Intervention: Low methadone dose (10-25 mg/day)
Number of subjects: 7
Study 26188663 — intervention group
Group type: COMPARATOR
Intervention: Control group (cigarette smoking-matched)
Number of subjects: 7
Study 23679146 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling Group (NCG)
Number of subjects: 39
Study 23679146 — intervention group
Group type: COMPARATOR
Intervention: Ad Libitum Group (ALG)
Number of subjects: 39
Study 23679146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (NCG and ALG)
Number of subjects: 39
Study 21469942 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL syringe
Number of subjects: 223
Study 21469942 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL syringe
Number of subjects: 223
Study 21469942 — intervention group
Group type: COMPARATOR
Intervention: 10 mL syringe
Number of subjects: 223
Study 21469942 — intervention group
Group type: EXPERIMENTAL
Intervention: Various syringe sizes (1, 3, 5, 10, 20, 60 mL)
Number of subjects: 223
Study 19644851 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose D-penicillamine
Number of subjects: 0
Study 19644851 — intervention group
Group type: COMPARATOR
Intervention: Low-dose D-penicillamine
Number of subjects: 0
Study 19644851 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human relaxin
Number of subjects: 0
Study 19644851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for relaxin)
Number of subjects: 0
Study 19644851 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bovine type I collagen
Number of subjects: 0
Study 19644851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for collagen)
Number of subjects: 0
Study 17473738 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser suture lysis (LSL)
Number of subjects: 48
Study 17473738 — intervention group
Group type: COMPARATOR
Intervention: Releasable sutures
Number of subjects: 48
Study 16045374 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 322
Study 11728835 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate at low plasma levels (0.1-0.3 ng/ml)
Number of subjects: 31
Study 11728835 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate at medium plasma levels (0.3-0.6 ng/ml)
Number of subjects: 31
Study 11728835 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate at high plasma levels (0.6-1.0 ng/ml)
Number of subjects: 31
Study 11728835 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study 9468782 — intervention group
Group type: EXPERIMENTAL
Intervention: Video tape
Number of subjects: 80
Study 9468782 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture book
Number of subjects: 80
Study 9468782 — intervention group
Group type: EXPERIMENTAL
Intervention: Both video tape and picture book
Number of subjects: 80
Study 9468782 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrelated materials)
Number of subjects: 80
Study 7657402 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically-guided self-help (CGSH) program plus standard treatment (methadone maintenance plus individual counseling)
Number of subjects: 3
Study 7657402 — intervention group
Group type: COMPARATOR
Intervention: Didactic lecture program plus standard treatment
Number of subjects: 3
Study 7657402 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 3
Study 2762658 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen (400 mg/die)
Number of subjects: 40
Study 2762658 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 40
Study 805623 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG anti‐K (13‐14 mug)
Number of subjects: 62
Study 805623 — intervention group
Group type: COMPARATOR
Intervention: Control (no IgG anti‐K)
Number of subjects: 62
Study 31659597 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative systemic immune-inflammation index (SII) calculated as (neutrophil) × (platelet)/(lymphocyte) with a cutoff value of 843; evaluated for cancer-specific survival (CSS) and overall survival (OS).
Number of subjects: 191
Study 30904909 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial autologous blood plus thrombin patch (ABP)
Number of subjects: 150
Study 30904909 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial occlusion using silicone spigots (BOS)
Number of subjects: 150
Study 30904909 — intervention group
Group type: COMPARATOR
Intervention: Chest tube‐attached water‐seal drainage (CTD)
Number of subjects: 150
Study 29025485 — intervention group
Group type: EXPERIMENTAL
Intervention: Household intervention
Number of subjects: 3061
Study 29025485 — intervention group
Group type: COMPARATOR
Intervention: Non-household intervention
Number of subjects: 3061
Study 25542552 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging in advance care planning (ACP) using online decision aid ('Making Your Wishes Known')
Number of subjects: 200
Study 25542552 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 200
Study 25542552 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging in ACP (Intervention group)
Number of subjects: 200
Study 25542552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (Engaging in ACP)
Number of subjects: 200
Study 23636085 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration treatment during 17 sessions
Number of subjects: 20
Study 23636085 — intervention group
Group type: COMPARATOR
Intervention: Sham group performing the same exercises without vibration
Number of subjects: 20
Study 21612611 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐134 50 mg
Number of subjects: 199
Study 21612611 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐134 100 mg
Number of subjects: 199
Study 21612611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 21612611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 199
Study 21612611 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐134 25 mg
Number of subjects: 199
Study 19386794 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-based driving training
Number of subjects: 83
Study 19386794 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training
Number of subjects: 83
Study 15674004 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki treatment by experienced Reiki practitioner
Number of subjects: 45
Study 15674004 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment by a person with no knowledge of Reiki
Number of subjects: 45
Study 15674004 — intervention group
Group type: COMPARATOR
Intervention: No treatment (rest only)
Number of subjects: 45
Study 10334756 — intervention group
Group type: EXPERIMENTAL
Intervention: individual‐cluster trials
Number of subjects: 0
Study 10334756 — intervention group
Group type: EXPERIMENTAL
Intervention: cluster‐cluster trials
Number of subjects: 0
Study 7484044 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 100 micrograms.h‐1
Number of subjects: 24
Study 7484044 — intervention group
Group type: COMPARATOR
Intervention: Placebo system
Number of subjects: 24
Study 2258442 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain waterbed
Number of subjects: 52
Study 2258442 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuously oscillating waterbed
Number of subjects: 52
Study 2258442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittently oscillating waterbed
Number of subjects: 52
Study 2258442 — intervention group
Group type: COMPARATOR
Intervention: Control group (incubator mattress)
Number of subjects: 52
Study 7029297 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, dactinomycin, and cyclophosphamide (VAC) for 2 years after excision of localized tumor (group I)
Number of subjects: 780
Study 7029297 — intervention group
Group type: COMPARATOR
Intervention: Vincristine combined with dactinomycin with postoperative irradiation (group II)
Number of subjects: 780
Study 7029297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy regimens, 'pulse' VAC alone or VAC combined with adriamycin followed by irradiation (group III)
Number of subjects: 780
Study 7029297 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with metastatic disease at diagnosis (group IV)
Number of subjects: 780
Study 31651889 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose HT047 (750 mg 3 times a day)
Number of subjects: 78
Study 31651889 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose HT047 (500 mg 3 times a day)
Number of subjects: 78
Study 31651889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 28830927 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling intervention (4 sessions)
Number of subjects: 13
Study 28830927 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 6)
Number of subjects: 13